Matthew Cormier
Overview
Explore the profile of Matthew Cormier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
30
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cormier M, Burnett E, Mo A, Notley C, Tijet N, Christie-Holmes N, et al.
J Thromb Haemost
. 2023 Sep;
22(1):76-89.
PMID: 37678547
Background: One-third of patients with severe hemophilia A develop neutralizing antibodies to the factor VIII (FVIII) protein in response to intravenous replacement therapy. Patients may also generate natural, nonneutralizing antibodies...
2.
Choi S, Dwyer C, Rapkin L, Cormier M, Hindmarch C, Nesbitt K, et al.
J Thromb Haemost
. 2023 Jan;
21(3):586-598.
PMID: 36696220
Background: Although the concept of immunothrombosis has established a link between inflammation and thrombosis, the role of inflammation in the pathogenesis of deep vein thrombosis remains to be fully elucidated....
3.
Cormier M, Cushman M
Res Pract Thromb Haemost
. 2021 Apr;
5(3):373-375.
PMID: 33870022
No abstract available.
4.
Othman M, Cormier M, Barnes G, Comer S, Connors J, Denorme F, et al.
Res Pract Thromb Haemost
. 2021 Mar;
5(2):253-260.
PMID: 33733023
As a result of the coronavirus disease 2019 pandemic, the International Society on Thrombosis and Haemostasis (ISTH), like many societies around the world, canceled their in-person hematology congress planned for...
5.
Tarrant J, Cormier M, Nesbitt K, Dwyer C, Hough C, Lillicrap D
Blood Adv
. 2020 Jun;
4(12):2644-2655.
PMID: 32556285
The development of neutralizing FVIII antibodies is the most serious complication of hemophilia A treatment. The currently known patient- and treatment-related risk factors for inhibitor development do not accurately predict...
6.
Cormier M, Batty P, Tarrant J, Lillicrap D
Br J Haematol
. 2020 Feb;
189(1):39-53.
PMID: 32064603
Anti-drug antibody formation following factor VIII (FVIII) replacement therapy is the most important treatment-related complication in patients with severe haemophilia A. A significant number of these antibodies show neutralising activity...